Effectiveness and Cost-Utility Analysis of Different Doses of Irinotecan Plus Bevacizumab in Patients With Metastatic Colorectal Cancer: A Long-Term and Prospective Cohort Study.

MLA

Shi, Hon-Yi, et al. “Effectiveness and Cost-Utility Analysis of Different Doses of Irinotecan Plus Bevacizumab in Patients With Metastatic Colorectal Cancer: A Long-Term and Prospective Cohort Study.” Frontiers in Oncology, vol. 12, Mar. 2022, p. 756078. EBSCOhost, https://doi.org/10.3389/fonc.2022.756078.

APA

Shi, H.-Y., Chen, Y.-C., Huang, C.-W., Li, C.-C., Su, W.-C., Chang, T.-K., Chen, P.-J., Yin, T.-C., Tsai, H.-L., & Wang, J.-Y. (2022). Effectiveness and Cost-Utility Analysis of Different Doses of Irinotecan Plus Bevacizumab in Patients With Metastatic Colorectal Cancer: A Long-Term and Prospective Cohort Study. Frontiers in Oncology, 12, 756078. https://doi.org/10.3389/fonc.2022.756078

Chicago

Shi, Hon-Yi, Yen-Cheng Chen, Ching-Wen Huang, Ching-Chun Li, Wei-Chih Su, Tsung-Kun Chang, Po-Jung Chen, Tzu-Chieh Yin, Hsiang-Lin Tsai, and Jaw-Yuan Wang. 2022. “Effectiveness and Cost-Utility Analysis of Different Doses of Irinotecan Plus Bevacizumab in Patients With Metastatic Colorectal Cancer: A Long-Term and Prospective Cohort Study.” Frontiers in Oncology 12 (March): 756078. doi:10.3389/fonc.2022.756078.